InvestWiser

NextCell Pharma AB

NXTCLNasdaq StockholmHealthcareMarket value 29 m SEK
0.23SEK −6.7%
last day · Price as of 18 November 2026

The answer first

Does NextCell Pharma beat the market?

No, NextCell Pharma has not beaten the market over the last year.

NextCell Pharma−71.0%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 61% of Nordic stocks

    • Quality73
    • Value78
    • Trend20

    No. 46 of 195 in healthcare

Max for seven days

Follow NextCell Pharma with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on NextCell Pharma

From today, at a price of 0.23 SEK. Write why you follow NextCell Pharma, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about NextCell Pharma

Your first answer is free, no account needed.

Do you own NextCell Pharma, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with NextCell Pharma and a few more. Free, no card.

Past year against the exchange and Super Stock
NextCell Pharma−71.0%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • NextCell Pharma has fallen 71.0% over the past year, including dividends.
  • Overall, NextCell Pharma ranks better than 61% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 94.0%. The price is 98.9% below its peak now.

What do analysts think of NextCell Pharma?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

61

Quality, value and trend together. Better than 61% of Nordic stocks.

No. 46 of 195 in healthcare

Quality73
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 77 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity–
  • Asset turnoverSales divided by everything the company owns0.16
  • Return on equityProfit divided by equity−94.5%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value78
The price · Valuation: the multiples

High Low price: you pay little for what the company earns and owns.

No. 14 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity0.6
  • P/SPrice divided by sales2.7
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend20
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 125 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−80.7%
  • 6 months−82.0%
  • 9 months−85.5%
  • 12 months−71.0%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−77.2%
3 years, per year
−53.9%
5 years, per year
−48.5%
Year to date
−68.8%
Largest fall, 3 years
−94.0%
From a peak to the bottom
From the peak now
−98.9%
How far the price is from the peak
Volatility, 1 year
119.6%
How much the price swings over a year
Beta, 1 year
0.43
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own NextCell Pharma

One fund we follow owns NextCell Pharma. The share is how much of the fund the stock makes up.

  • Sweden1

From the funds' latest known holdings.

About NextCell Pharma

NextCell Pharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 24 employees.

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank; and QVance, the first dedicated provider of quality services for developers of advanced therapies. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.

See the full analysis of NextCell Pharma.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market